Uli Brödl, MD
Chief Scientific Officer (CSO)
Member of the Corporate Executive Board
Prof. Dr. Uli Brödl was born in 1972 and assumed the role of Head of Research & Development, Chief Scientific Officer (“CSO”), and as a member of the Corporate Executive Board in February 2025. He has more than 15 years of industry experience and joined Grünenthal from Boehringer Ingelheim, where he served as Corporate Senior Vice President, Head of Global Clinical Development & Operations, and member of Boehringer Ingelheim's Venture Fund Investment Committee.
Earlier in his career, Uli led the clinical development of Jardiance (empagliflozin) at Boehringer Ingelheim, resulting in the successful registration of Jardiance as the first glucose-lowering medication to reduce the risk of cardiovascular death in patients with type 2 diabetes mellitus and established cardiovascular disease.
Uli Brödl at a glance
- Nationality: German
- Year of birth: 1972
- Education: Medical Doctor at Ludwig-Maximilians University Munich; board-certified internist and endocrinologist and Adjunct Professor for Internal Medicine at the Ludwig-Maximilians University Munich
- Family status: Married, three children
- Leisure time: Running, skiing and playing the piano
Career highlights
- Since 2025: Head of Research & Development, Chief Scientific Officer, Member of the Corporate Executive Board; Grünenthal
- 2020-2025: Head of Global Clinical Development & Operations, Member of the Bi Venture Fund Investment Committee; Boehringer Ingelheim
- 2017-2020: Country Medical Director and Vice President Medical and Regulatory Affairs; Boehringer Ingelheim Canada Ltd., Founder and Co-Chair BI Canada Incubator
- 2009-2016: Global Head Late Clinical Development, TA Metabolism, Boehringer Ingelheim
- 2008: German Board Certification in Endocrinology, Diabetes and Metabolism; Ludwig-Maximilians-Universität (LMU) Munich
- 2007: German Board Certification in Internal Medicine; Ludwig-Maximilians-Universität (LMU) Munich